Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01861457 · ClinicalTrials.gov registry record · NA

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

A NA study of Infectious Disease, sponsored by Medical University of South Carolina.

Completed
Registry status
NA
Development phase
39
Enrollment target
1
Study location

NCT01861457: Completed NA study of Infectious Disease, sponsored by Medical University of South Carolina.

NCT01861457 is a NA study of Infectious Disease that has completed, run by Medical University of South Carolina. The registered enrollment target is 39 participants, below the 7,023-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01861457, a NA study of Infectious Disease, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the extent to which bacterial growth in the nostrils by S. aureus, a common bacteria that is found in hospital environment, can be reduced by NOZIN® Nasal Sanitizer® antiseptic nasal swabs during the course of a typical 10-hour work period in participants known to have S. aureus in their nose passages.

Primary Outcome

The percent change from morning baseline sample to the evening sample taken at the end of a typical 10-hour workday in treated subjects known to be colonized by Staph aureus.

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Nozin® Nasal Sanitizer®

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2013-01
Est. Completion 2013-05
Phase NA

What the finished NCT01861457 record still lists

NCT01861457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 7,023-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Infectious Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01861457 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT01861457 about?

NCT01861457 is a clinical study titled "Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic". The purpose of this study is to determine the extent to which bacterial growth in the nostrils by S. aureus, a common bacteria that is found in hospital environment, can be reduced by NOZIN® Nasal Sanitizer® antiseptic nasal swabs during the course of a typical 10-hour work period in participants kn...

What is the current status of trial NCT01861457?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2013-01. Estimated completion is 2013-05.

What conditions does trial NCT01861457 study?

This clinical trial studies the following conditions: Infectious Disease.

What interventions are being tested in trial NCT01861457?

The interventions under investigation include: Placebo (OTHER), Nozin® Nasal Sanitizer® (OTHER).

Who is sponsoring clinical trial NCT01861457?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01861457 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infectious Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01861457's enrollment target sits among peer trials

39 16th of 18 higher than 3 of 18 other Infectious Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infectious Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01861457, the US trial registry maintained by the National Library of Medicine. NCT01861457 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.